Ligands of Immunopharmacology

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 ( mTLR4/MD-2 ) agonist with an EC 50 of 18.5 μM.In VitroNeoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC 50 of 18.5 μM.

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 ( mTLR4/MD-2 ) agonist with an EC 50 of 18.5 μM.In VitroNeoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC 50 of 18.5 μM.

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 ( mTLR4/MD-2 ) agonist with an EC 50 of 18.5 μM.In VitroNeoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC 50 of 18.5 μM.

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 ( mTLR4/MD-2 ) agonist with an EC 50 of 18.5 μM.In VitroNeoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC 50 of 18.5 μM.

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 ( mTLR4/MD-2 ) agonist with an EC 50 of 18.5 μM.In VitroNeoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC 50 of 18.5 μM.

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 ( mTLR4/MD-2 ) agonist with an EC 50 of 18.5 μM.In VitroNeoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC 50 of 18.5 μM.

Nepafenac-d 5 is the deuterium labeled Nepafenac, which is a selective COX-2 inhibitor .Form:Solid

Nepafenac-d 5 is the deuterium labeled Nepafenac, which is a selective COX-2 inhibitor .Form:Solid

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be